<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Surg Oncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann. Surg. Oncol</journal-id>
      <journal-title-group>
        <journal-title>Annals of Surgical Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1068-9265</issn>
      <issn pub-type="epub">1534-4681</issn>
      <publisher>
        <publisher-name>Springer US</publisher-name>
        <publisher-loc>Boston</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24006094</article-id>
      <article-id pub-id-type="pmc">3929768</article-id>
      <article-id pub-id-type="publisher-id">3213</article-id>
      <article-id pub-id-type="doi">10.1245/s10434-013-3213-1</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Gastrointestinal Oncology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Solass</surname>
            <given-names>Wiebke</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kerb</surname>
            <given-names>Reinhold</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="Aff2"/>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>M&#xFC;rdter</surname>
            <given-names>Thomas</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="Aff2"/>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Giger-Pabst</surname>
            <given-names>Urs</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Strumberg</surname>
            <given-names>Dirk</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tempfer</surname>
            <given-names>Clemens</given-names>
          </name>
          <degrees>MD, MBA</degrees>
          <xref ref-type="aff" rid="Aff6"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zieren</surname>
            <given-names>J&#xFC;rgen</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schwab</surname>
            <given-names>Matthias</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="Aff2"/>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Reymond</surname>
            <given-names>Marc Andr&#xE9;</given-names>
          </name>
          <degrees>MD, MBA</degrees>
          <address>
            <email>marc.reymond@yahoo.de</email>
          </address>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <aff id="Aff1"><label/>Institute of Pathology, Ruhr-University Bochum, Bochum, Germany </aff>
        <aff id="Aff2"><label/>Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany </aff>
        <aff id="Aff3"><label/>Department of Clinical Pharmacology, University Hospital, T&#xFC;bingen, Germany </aff>
        <aff id="Aff4"><label/>Department of Surgery, Marienhospital Herne, Ruhr-University Bochum, Bochum, Germany </aff>
        <aff id="Aff5"><label/>Department of Internal Medicine, Oncology and Hematology, Marienhospital Herne, Ruhr-University Bochum, Bochum, Germany </aff>
        <aff id="Aff6"><label/>Department of Gynaecology and Obstetrics, Marienhospital Herne, Ruhr-University Bochum, Bochum, Germany </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>5</day>
        <month>9</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>5</day>
        <month>9</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2014</year>
      </pub-date>
      <volume>21</volume>
      <issue>2</issue>
      <fpage>553</fpage>
      <lpage>559</lpage>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>4</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2013</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Peritoneal carcinomatosis (PC) is an unmet medical need. Despite recent improvements, systemic chemotherapy has limited efficacy. We report the first application of intraperitoneal chemotherapy as a pressurized aerosol in human patients.
</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>Three end-stage patients with advanced PC from gastric, appendiceal, and ovarian origin were treated as a compassionate therapy. All patients had received previous systemic chemotherapy. A pressurized aerosol of CO<sub>2</sub> loaded with doxorubicin 1.5&#xA0;mg/m<sup>2</sup> and cisplatin 7.5&#xA0;mg/m<sup>2</sup> (pressurized intraperitoneal aerosol chemotherapy, PIPAC) was applied into the abdomen for 30&#xA0;min at a pressure of 12&#xA0;mmHg and a temperature of 37&#xA0;&#xB0;C.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>No side-effects &gt;2 CTCAE were observed, and the procedures were well tolerated. Early hospital discharge was possible (days 2&#x2013;5). Nuclear presence of doxorubicin was documented throughout the peritoneum, reaching high local concentration (&#x2264;4.1&#xA0;&#x3BC;mol/g) and plasma concentration was low (4.0&#x2013;6.2&#xA0;ng/ml). PIPAC created no significant adhesions, could be repeated, and was applied 6&#xD7;, 4&#xD7;, and 2&#xD7;. Two patients showed a complete and one a partial histological remission. Mean survival after the first PIPAC was 288&#xA0;days. One patient is alive after 567&#xA0;days.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>PIPAC shows superior pharmacological properties with high local concentration and low systemic exposure. PIPAC can induce regression of PC in chemoresistant tumors, using 10&#xA0;% of a usual systemic dose.</p>
        </sec>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (doi:10.1245/s10434-013-3213-1) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Society of Surgical Oncology 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Life expectancy in peritoneal carcinomatosis (PC) is limited due to advanced tumor stage and poor therapeutic response. Resistance of PC to systemic chemotherapy (SC) is explained by molecular mechanisms and by limited drug distribution.<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref> This is the rationale for locoregional therapy combining cytoreductive surgery (CRS) with intraperitoneal chemotherapy (IPC).<xref ref-type="bibr" rid="CR3">3</xref> However, this approach is debated: IPC is hampered by limited drug distribution within the abdominal cavity and poor penetration into PC nodules.<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref> Thus, the benefit of combined CRS and IPC compared with CRS alone might be marginal.<xref ref-type="bibr" rid="CR6">6</xref></p>
    <p>We have proposed to apply chemotherapy as a pressurized aerosol within the abdominal cavity to take advantage of following physical properties: applying an aerosol allows a homogeneous repartition of the substance within a closed space; generating an artificial pressure gradient counterbalances tumoral interstitial fluid pressure, an obstacle in cancer therapy.<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref> In the large animal model, pressurized aerosol improved both distribution of a vital staining within the abdominal cavity, and depth of penetration into the peritoneum, as compared to peritoneal lavage with a liquid solution.<xref ref-type="bibr" rid="CR9">9</xref> When treating human PC ex vivo, we achieved a superior distribution onto the peritoneum and a better penetration into PC nodules than IPC.<xref ref-type="bibr" rid="CR10">10</xref> This was the rationale for the first application in the human patient.</p>
    <sec id="Sec1" sec-type="materials|methods">
      <title>Methods</title>
      <sec id="Sec2">
        <title>Patients</title>
        <p>Pressurized intraperitoneal aerosol chemotherapy (PIPAC) was offered as a treatment option to three patients suffering from a fatal disease for which no satisfactory alternative therapy was available, pursuant to the individual compassionate use of medicinal products according to the German Medical Act (AMG) and with documented favorable opinion by the Ethics Committees of the University of M&#xFC;nster, Germany. Patients were evaluated by our multidisciplinary team before onset of treatment and provided written, informed consent. Clinical and histological confirmation of PC, including small bowel involvement, was required. No patient had parenchymatous metastases. Patient histories are summarized in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>. PIPACs were performed between November 2011 and March 2013.<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Patient characteristics and therapy summary</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Patient</th><th align="left">Sex</th><th align="left">Age at first PIPAC</th><th align="left">Diagnosis</th><th align="left">First diagnosis</th><th align="left">Previous surgery</th><th align="left">Previous chemotherapy regimen</th><th align="left">Karnovsky before therapy (%)</th><th align="left">PCI before PIPAC therapy</th><th align="left">PIPAC procedures (n)</th><th align="left">Secondary CRS</th><th align="left">Adverse effects (Grade CTAEC)</th><th align="left">Intraperitoneal tumor remission: macroscopy</th><th align="left">Intraperitoneal tumor remission: histology</th><th align="left">Tumor ascites control</th><th align="left">Max. Karnovsky after therapy (%)</th><th align="left">Status</th><th align="left">Cause of death</th><th align="left">Survival (days)</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">M</td><td align="left">38</td><td align="left">Gastric Ca, signet ring</td><td align="left">2009 (2&#xA0;years)</td><td align="left">Gastrectomy, LAD D2</td><td align="left">ECF, paclitaxel (disease progression)</td><td align="left">40</td><td align="left">6</td><td align="left">2</td><td align="left">No</td><td align="left">Fever (2), vomiting (2), Pain (2)</td><td align="left">CR</td><td align="left">CR</td><td align="left">N/A</td><td align="left">40</td><td align="left">Dead</td><td align="left">Metastasis, cachexia</td><td align="left">109</td></tr><tr><td align="left">2</td><td align="left">M</td><td align="left">45</td><td align="left">Appendix Ca, signet ring</td><td align="left">9.2011 (6&#xA0;weeks)</td><td align="left">Ileo-caecal resection</td><td align="left">5-FU (adverse effects)</td><td align="left">40</td><td align="left">16</td><td align="left">4</td><td align="left">Yes</td><td align="left">Bowel perforation (4)<sup>a</sup>
</td><td align="left">PR</td><td align="left">PR</td><td align="left">N/A</td><td align="left">70</td><td align="left">Dead</td><td align="left">Bowel obstruction</td><td align="left">187</td></tr><tr><td align="left">3</td><td align="left">F</td><td align="left">73</td><td align="left">Ovarian Ca</td><td align="left">2001 (10&#xA0;years)</td><td align="left">Hysterectomy, adnexectomy, LAD</td><td align="left">Multiple regimen</td><td align="left">40</td><td align="left">14</td><td align="left">6</td><td align="left">No</td><td align="left">Fatigue (1)</td><td align="left">CR</td><td align="left">CR</td><td align="left">Yes</td><td align="left">90</td><td align="left">Alive</td><td align="left">N/A</td><td align="left">567</td></tr></tbody></table><table-wrap-foot><p>
<italic>PIPAC</italic> pressurized intraperitoneal aerosol chemotherapy, <italic>PCI</italic> peritoneal carcinomatosis index, <italic>CRS</italic> cytoreductive surgery, <italic>N/A</italic> no ascites, <italic>LAD</italic> lymphadenectomy, <italic>PR</italic> partial (intraperitoneal) remission, <italic>CR</italic> complete (intraperitoneal) remission</p><p>
<sup>a</sup>Bowel perforation after CRS combined with PIPAC</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec3">
        <title>Surgical Procedures</title>
        <p>PIPAC is described in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>. After insufflation of a 12&#xA0;mmHg of capnoperitoneum at 37&#xA0;&#xB0;C, two balloon trocars (Applied Medical, D&#xFC;sseldorf) were placed. Explorative laparoscopy was performed as usual and PC index was determined.<xref ref-type="bibr" rid="CR11">11</xref> Parietal biopsies were taken and ascites was removed. A nebulizer (MIP, Reger Medizintechnik, Rottweil) was connected to a high-pressure injector (Injektron 82M, MedTron, Saarbruecken) and inserted into the abdomen through a trocar. A pressurized aerosol containing cisplatin (Hexal, Barleben) at a dose of 7.5&#xA0;mg/m<sup>2</sup> body surface in 150&#xA0;ml NaCl 0.9&#xA0;% was applied immediately followed by doxorubicin (Hexal, Barleben) 1.5&#xA0;mg/m<sup>2</sup> in 50&#xA0;ml NaCl 0.9&#xA0;%. Then, the system was kept in steady-state for 30&#xA0;min (application time). Toxic aerosol was exhausted over a closed system. Trocars were retracted. PIPAC was repeated two to five times at various time intervals. Occupational health safety aspects are described elsewhere.<xref ref-type="bibr" rid="CR12">12</xref><fig id="Fig1"><label>Fig.&#xA0;1
</label><caption><p>Pressurized intraperitoneal aerosol chemotherapy (PIPAC). The procedure is performed in an operating room equipped with laminar air-flow and is remote-controlled. In a first step, a normothermic capnoperitoneum is established with a pressure of 12&#xA0;mmHg at body temperature. A chemotherapy solution (about 10&#xA0;% of a normal systemic dose) is nebulized with a micropump into the tightly closed abdominal cavity, and maintained for 30&#xA0;min. The toxic aerosol is then exhausted through a closed system and released into the external environment</p></caption><graphic xlink:href="10434_2013_3213_Fig1_HTML" id="MO1"/></fig></p>
      </sec>
      <sec id="Sec4">
        <title>Safety and Efficacy Assessments</title>
        <p>Assessments for patient safety and tolerability were performed from days 1&#x2013;5 after treatment and included medical examination and routine laboratory measures. Adverse effects were graded according to the NCI Criteria for Adverse Events (CTCAE).<xref ref-type="bibr" rid="CR13">13</xref> Tumor response was assessed by laparoscopy with macroscopic assessment and histology, as part of the next PIPAC cycle. Patients were followed up for analysis until June 20, 2013 or until death.</p>
      </sec>
      <sec id="Sec5">
        <title>Histology</title>
        <p>Biopsies were analyzed for possible tumor response by conventional HE microscopy.</p>
      </sec>
      <sec id="Sec6">
        <title>Clinical Pharmacology</title>
        <p>Analysis is based on eight PIPAC in three patients. Blood samples were drawn before, during, and up to 12&#xA0;h after start of PIPAC. At the end of PIPAC, biopsies from peritoneal tissue and tumor nodules were snap-frozen. Doxorubicin plasma levels were determined by UHPLC-MS/MS using [13C2H3]-doxorubicin as internal standard. Pharmacokinetics parameters were derived by non-compartmental analysis (WinNonLin 6.3, Pharsight, Cary, NC, USA). The area under the plasma concentration-time curve (AUC) was calculated by the linear trapezoidal rule.</p>
      </sec>
    </sec>
    <sec id="Sec7" sec-type="results">
      <title>Results</title>
      <sec id="Sec8">
        <title>Patient 1</title>
        <p>A 45-year-old male patient was operated because of acute bowel obstruction due to PC from signet-ring appendiceal cancer. Postoperative high-dose chemotherapy (5-FU) was interrupted due to acute heart failure. After recovery, Karnovsky index was 40&#xA0;%. First PIPAC was performed, showing a PCI of 16 (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>a1, b1). Four weeks later, second PIPAC showed stable disease. Four weeks later, 3rd PIPAC showed hard, glassy nodules (a2), histology showed regressive changes with nodular sclerosis (b2). Six weeks later, small bowel nodules were regressive (a3), histology showed regressive changes with 60&#xA0;% vital cells and large devitalized areas (b3). Complete CRS was performed, and fourth PIPAC administered. A postoperative bowel perforation required surgical revision. After recovery, the patient developed bowel obstruction and tumor progression was confirmed by laparotomy. He died 187&#xA0;days after first PIPAC.<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>Macroscopical and histological response after PIPAC. Forty-five year male patient with diffuse peritoneal carcinomatosis (PCI&#xA0;=&#xA0;16) from a signet-ring cells appendiceal cancer with inaugural small bowel obstruction. Macroscopy before (<bold>a1</bold>), after 1st (<bold>a2</bold>) and after 3rd PIPAC (<bold>a3</bold>) showing regression of small bowel PC nodules. Histology shows vital tumor before PIPAC (<bold>b1</bold>), inflammatory reaction with nodular sclerosis after 1st PIPAC (<bold>b2</bold>) and large areas of devitalized tumor after 3rd PIPAC (<bold>b3</bold>). <italic>Scale bar</italic> 100&#xA0;&#xB5;m
</p></caption><graphic xlink:href="10434_2013_3213_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
      <sec id="Sec9">
        <title>Patient 2</title>
        <p>A 38-year-old male patient with a 2-year history of signet-ring gastric cancer, gastrectomy, and two chemotherapy lines presented with tumor progression and end-stage disease requiring parenteral nutrition. Karnovsky index was 40&#xA0;%. A PCI of 6 was documented at first PIPAC (Supplementary material 1, a1). Four weeks later, during the second PIPAC, macroscopy showed complete remission (a2), and multiple biopsies confirmed absence of tumor cells (b2). Eight weeks later, the patient developed liver and bone metastases and died 109&#xA0;days after the first PIPAC. Two weeks before death, abdomen CT showed no evidence of PC.</p>
      </sec>
      <sec id="Sec10">
        <title>Patient 3</title>
        <p>A 73-year-old female patient with a 10-year history of ovarian cancer, surgery, and multiple chemotherapy regimens presented with tumor progression and hemorrhagic ascites. Karnovsky index was 40&#xA0;%. At first PIPAC, a PCI of 14 was documented and 2.5&#xA0;l ascites removed (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>a1, b1). At second PIPAC after 4&#xA0;weeks, PC nodules were hard and glassy, and ascites volume dropped to 1&#xA0;l. Histology showed no regression (not shown). Six weeks later at the third PIPAC, ascites was &lt;500&#xA0;ml (a2), and histology showed partial tumor response with fibrotic reaction (b2). Karnoswky index was 90&#xA0;%. Eight months after first PIPAC, fourth PIPAC showed complete remission (a3), and multiple biopsies showed apoptotic inflammatory cells (b3) but no tumor. After 15&#xA0;months of follow-up, the asymptomatic patient underwent control laparoscopy; tumor was documented in two of five peritoneal biopsies, so fifth PIPAC was applied. Six weeks later, a single, 6-cm, large tumor node was resected. All other biopsies were negative; sixth PIPAC was applied. After 567&#xA0;days, the patient is alive with an excellent quality of life.<fig id="Fig3"><label>Fig.&#xA0;3</label><caption><p>73-year-old patient (patient 3) with therapy-resistant peritoneal carcinomatosis and malignant ascites of ovarian origin. Shown is the macroscopic (<italic>upper</italic> fig) and histological (HE staining, <italic>lower</italic> fig) appearance before (<italic>left</italic> column), after PIPAC (<italic>middle</italic> column) and at later stages of follow-up (<italic>right</italic> column). <bold>a</bold>, <bold>b</bold> Show partial and then complete macroscopic and microscopic tumor remission after repeated PIPAC. <italic>Scale bar</italic> 100&#xA0;&#xB5;m</p></caption><graphic xlink:href="10434_2013_3213_Fig3_HTML" id="MO3"/></fig></p>
      </sec>
      <sec id="Sec11">
        <title>Safety</title>
        <p>All 11 PIPAC procedures were technically easy to perform. For PIPAC alone, mean operating time was 93&#xA0;&#xB1;&#xA0;13&#xA0;min. No intraoperative complication was noted. PIPAC alone was very well tolerated, no adverse effect &gt;2 CTCAE was noted (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). After PIPAC alone, patients were discharged from hospital 2&#x2013;5&#xA0;days after treatment. In two instances, PIPAC was combined with another operation (small-bowel resection, complete cytoreductive surgery): in the latter case, a postoperative bowel perforation (see Patient 1 above) required surgical revision.</p>
      </sec>
      <sec id="Sec12">
        <title>Clinical Pharmacology</title>
        <p>The plasma concentration-time curve fitted best to a two-compartment model with first-order absorption. Peak doxorubicin plasma concentrations were low (4.0&#x2013;6.2&#xA0;ng/ml) and were reached with the end of nebulisation. Doxorubicin was eliminated from the body with a clearance (Cl/F) of 2.6&#x2013;6.0&#xA0;ml/min. Half-lives and AUCs ranged from 86 to 468&#xA0;min and 415 to 915&#xA0;ng/ml&#xA0;min, respectively (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>a). Tissue concentration of doxorubicin was high (mean 1.7&#xA0;&#x3BC;g/g) and variable (SD&#xA0;&#xB1;&#xA0;1.45&#xA0;&#x3BC;g/g). In tumor nodules, fluorescence microscopy showed nuclear presence of doxorubicin up to 500&#xA0;&#x3BC;m depth (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>b) and throughout the whole peritoneal layer into the properitoneal fatty tissue (&gt;600&#xA0;&#x3BC;m, Supplementary material 2). Highest concentration was achieved within 100&#x2013;200&#xA0;&#x3BC;m from the surface.<fig id="Fig4"><label>Fig.&#xA0;4</label><caption><p>Local and systemic doxorubicin exposure during PIPAC. Local disposition is high with 1.70&#xA0;&#xB1;&#xA0;1.45&#xA0;&#xB5;g/g. In <bold>a</bold> fluorescence microscopy shows a nuclear presence of doxorubicin up to 500&#xA0;&#xB5;m depth. <italic>Red</italic> doxorubicin. <italic>Green</italic> picogreen nuclear counterstaining. <italic>Scale bar</italic> 100&#xA0;&#xB5;m. <bold>b</bold> Shows a typical pharmacokinetic profile in peripheral venous blood after PIPAC with doxorubicin 1.5&#xA0;mg/m<sup>2</sup> body surface for 30&#xA0;min at an intraabdominal pressure of 12&#xA0;mmHg. Peak doxorubicin plasma concentrations were low (4.0&#x2013;6.2&#xA0;ng/ml). <italic>Line</italic> predicted profile. <italic>Dots</italic> experimental values</p></caption><graphic xlink:href="10434_2013_3213_Fig4_HTML" id="MO4"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec13" sec-type="discussion">
      <title>Discussion</title>
      <p>To our knowledge, this is the first report of successful application of chemotherapy as a pressurized aerosol within the abdomen of human patients. It has been predicted that innovative concepts overcoming pharmacologic limitations of IPC could improve, perhaps dramatically, its efficacy.<xref ref-type="bibr" rid="CR5">5</xref> A superior dose&#x2013;response ratio after PIPAC could be expected from preclinical data. In the human patient, plasma concentration-time profile analysis now confirms such superior ratio between dose, systemic, and local drug concentration: PIPAC required only 1/10 of the doxorubicin dose to achieve higher tumor concentrations (0.03&#x2013;4.1&#xA0;&#x3BC;mol/g) as reported for HIPEC (0.02&#xA0;&#x3BC;mol/g).<xref ref-type="bibr" rid="CR15">15</xref> In contrast, systemic availability of doxorubicin after PIPAC and HIPEC were equal as indicated by the approximately ten times lower maximal plasma concentration after PIPAC.</p>
      <p>We and others have reported that increasing intraperitoneal pressure enhanced particularly the uptake of drugs into the tumor, resulting in a higher local disposition.<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref> After PIPAC, doxorubicin was not only detected in significant concentrations in PC nodules, but nuclear staining was demonstrated throughout the peritoneum, up to deeply into the retroperitoneal fatty tissue. Another explanation for superior local disposition could be the high drug concentration in the aerosol. Although used in only 1/10 of the total dose, doxorubicin concentration in the aerosol (52&#xA0;&#x3BC;M) is three times higher as in the intraperitoneal fluid usually used in HIPEC (18&#xA0;&#x3BC;M) without impairing tolerability, which was reported after applying higher concentrations of IPC.<xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR17">17</xref></p>
      <p>Tumor response was observed in all three cases after PIPAC, as a consequence of the well-documented antitumor activity of doxorubicin and cisplatin and the superior local disposition. However, we were surprised by the extent of macroscopic and microscopic response in these multidrug-resistant tumors. We documented a complete remission of PC in two patients, which was indeed unexpected.</p>
      <p>At this stage, it would be clearly premature to claim that combined PIPAC with cisplatin and doxorubicin improves survival in advanced PC. However, in our three patients with multiresistant tumors, low performance index, and very limited life expectancy, we observe a mean survival of more than 288&#xA0;days. Remarkably, 567&#xA0;days after her first PIPAC patient 3 is still alive.</p>
      <p>In sharp contrast to HIPEC, PIPAC was very well tolerated and the only severe adverse effect observed was a bowel perforation after CRS (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Otherwise, postoperative courses were uneventful, with early hospital discharge.</p>
      <p>PIPAC might create synergies with SC. Liver and renal tests showed neither acute nor cumulative toxicity after PIPAC, which appears reasonable bearing in mind the 90&#xA0;% dose reduction compared with conventional SC.<xref ref-type="bibr" rid="CR19">19</xref> Moreover, PIPAC permits repeated cycles of IPC and therefore might allow effective regimen combining SC and PIPAC. Importantly, repeated laparoscopy enables objective staging, assessment of therapeutic response, and adaptation of further therapy accordingly, which was barely possible until now. Finally, considering that all three patients were in poor physical condition with a low performance index, PIPAC might allow therapy in polymorbid patients&#x2014;when SC is contraindicated.</p>
      <p>We observed tumor regression even in platin-resistant tumors, after application of cisplatin and doxorubicin. This is not surprising since drug effect is usually dose-dependent. PIPAC might become an alternative therapy for platin-resistant tumors, in particular in women with ovarian cancer where tumor progression is diagnosed after first-line therapy with carboplatin&#x2013;Taxol. Repeated intraoperative analysis of the environmental air showed that PIPAC is safe for staff and meets the requirements of the German working safety regulations.<xref ref-type="bibr" rid="CR12">12</xref></p>
    </sec>
    <sec id="Sec14" sec-type="conclusion">
      <title>Conclusions</title>
      <p>These early data are promising: PIPAC can induce remission in end-stage, therapy-resistant PC, and first safety data are encouraging. PIPAC is well tolerated, a decisive feature in patients with limited life expectancy. By requiring only 10&#xA0;% of the dose of conventional IPC, PIPAC shows an excellent local distribution with low systemic exposure. Furthermore, PIPAC permits repeated cycles of IPC as well as objective tumor staging and response assessment. PIPAC is easy to use. PIPAC is complying with EC occupational safety regulations. The potential of this generic technology for a variety of indications and drugs has now to be determined with adequate studies.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Electronic supplementary material</title>
      <sec id="Sec15">
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="10434_2013_3213_MOESM1_ESM.jpg">
            <label>Supplementary Fig.&#xA0;1</label>
            <caption>
              <p>A 38-year male patient (patient 1) with a 2&#xA0;year history of signet-ring gastric cancer, gastrectomy and two chemotherapy lines. Macroscopy before <bold>a1</bold> and after 1st PIPAC <bold>a2</bold> showing vanishing of small bowel PC nodules. Histology <bold>b</bold> confirms complete remission of PC 4&#xA0;weeks after PIPAC. <italic>Scale bar</italic> 100&#xA0;&#xB5;m (JPEG 98&#xA0;kb)</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM2">
          <media xlink:href="10434_2013_3213_MOESM2_ESM.tif">
            <label>Supplementary Fig.&#xA0;2</label>
            <caption>
              <p>Fluorescence microscopy shows doxorubicin nuclear staining with doxorubicin (<italic>red</italic>) throughout the whole peritoneal layer into the properitoneal fatty tissue (&gt;600&#xA0;&#xB5;m). <italic>Green</italic> picogreen nuclear counterstaining. <italic>Scale bar</italic> 100&#xA0;&#xB5;m (TIFF 313&#xA0;kb)</p>
            </caption>
          </media>
        </supplementary-material>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgment</title>
      <p>This study was supported by Robert Bosch Foundation (Stuttgart, Germany) and the Federal Ministry for Education and Research (BMBF, Berlin, Germany) Grant #0316186D.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Griffiths</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Zee</surname>
              <given-names>YK</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Kumaran</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Welch</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Jayson</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Clamp</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Hasan</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube</article-title>
          <source>Int J Gynecol Cancer.</source>
          <year>2011</year>
          <volume>21</volume>
          <issue>1</issue>
          <fpage>58</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="doi">10.1097/IGC.0b013e3182049273</pub-id>
          <pub-id pub-id-type="pmid">21178570</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Minchinton</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Tannock</surname>
              <given-names>IF</given-names>
            </name>
          </person-group>
          <article-title>Drug penetration in solid tumours</article-title>
          <source>Nat Rev Cancer.</source>
          <year>2006</year>
          <volume>6</volume>
          <issue>8</issue>
          <fpage>583</fpage>
          <lpage>592</lpage>
          <pub-id pub-id-type="doi">10.1038/nrc1893</pub-id>
          <pub-id pub-id-type="pmid">16862189</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Macr&#xEC;</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fortugno</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Saladino</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Rationale and techniques of CRS and peritoneal chemohyperthermia</article-title>
          <source>World J Gastrointest Oncol.</source>
          <year>2011</year>
          <volume>3</volume>
          <issue>12</issue>
          <fpage>169</fpage>
          <lpage>174</lpage>
          <pub-id pub-id-type="doi">10.4251/wjgo.v3.i12.169</pub-id>
          <pub-id pub-id-type="pmid">22224171</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sugarbaker</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Ryan</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
          <article-title>Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach?</article-title>
          <source>Lancet Oncol.</source>
          <year>2012</year>
          <volume>13</volume>
          <issue>8</issue>
          <fpage>e362</fpage>
          <lpage>e369</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(12)70210-3</pub-id>
          <pub-id pub-id-type="pmid">22846841</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dedrick</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Flessner</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure</article-title>
          <source>J Natl Cancer Inst.</source>
          <year>1997</year>
          <volume>89</volume>
          <fpage>480</fpage>
          <lpage>487</lpage>
          <pub-id pub-id-type="doi">10.1093/jnci/89.7.480</pub-id>
          <pub-id pub-id-type="pmid">9086004</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elias</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gilly</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Boutitie</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Quenet</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bereder</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Mansvelt</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lorimier</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Dub&#xE8;</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Glehen</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study</article-title>
          <source>J Clin Oncol.</source>
          <year>2010</year>
          <volume>28</volume>
          <issue>1</issue>
          <fpage>63</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2009.23.9285</pub-id>
          <pub-id pub-id-type="pmid">19917863</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reymond</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator</article-title>
          <source>Surg Endosc.</source>
          <year>2000</year>
          <volume>14</volume>
          <fpage>51</fpage>
          <lpage>55</lpage>
          <pub-id pub-id-type="doi">10.1007/s004649900010</pub-id>
          <pub-id pub-id-type="pmid">10653236</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heldin</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Pietras</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ostman</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>High interstitial fluid pressure&#x2014;an obstacle in cancer therapy</article-title>
          <source>Nat Rev Cancer.</source>
          <year>2004</year>
          <volume>4</volume>
          <issue>10</issue>
          <fpage>806</fpage>
          <lpage>813</lpage>
          <pub-id pub-id-type="doi">10.1038/nrc1456</pub-id>
          <pub-id pub-id-type="pmid">15510161</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sola&#xDF;</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hetzel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nadiradze</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sagynaliev</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Reymond</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Description of a novel approach for intraperitoneal drug delivery and the related device</article-title>
          <source>Surg Endosc.</source>
          <year>2012</year>
          <volume>26</volume>
          <issue>7</issue>
          <fpage>1849</fpage>
          <lpage>1855</lpage>
          <pub-id pub-id-type="doi">10.1007/s00464-012-2148-0</pub-id>
          <pub-id pub-id-type="pmid">22580869</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Solass</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Herbette</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hetzel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Dutreix</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Reymond</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination capnoperitoneum: proof of concept</article-title>
          <source>Surg Endosc.</source>
          <year>2012</year>
          <volume>26</volume>
          <issue>3</issue>
          <fpage>847</fpage>
          <lpage>852</lpage>
          <pub-id pub-id-type="doi">10.1007/s00464-011-1964-y</pub-id>
          <pub-id pub-id-type="pmid">22042585</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elias</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Souadka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fayard</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mauguen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dumont</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Honore</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Goere</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Variation in the peritoneal cancer index scores between surgeons and according to when they are determined (before or after cytoreductive surgery)</article-title>
          <source>Eur J Surg Oncol.</source>
          <year>2012</year>
          <volume>38</volume>
          <issue>6</issue>
          <fpage>503</fpage>
          <lpage>508</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejso.2012.01.001</pub-id>
          <pub-id pub-id-type="pmid">22281154</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <mixed-citation publication-type="other">Sola&#xDF; W, Giger U, Borgstedt U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. <italic>Ann Surg Oncol.</italic> 2013 Jun 14 [Epub ahead of print].
</mixed-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm">http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm</ext-link>, Accessed 31 Dec 2012.</mixed-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sugarbaker</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Van der Speeten</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Anthony Stuart</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis</article-title>
          <source>Eur J Surg Oncol.</source>
          <year>2011</year>
          <volume>37</volume>
          <issue>8</issue>
          <fpage>719</fpage>
          <lpage>726</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejso.2011.04.007</pub-id>
          <pub-id pub-id-type="pmid">21621952</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jacquet</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Stuart</surname>
              <given-names>OA</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sugarbaker</surname>
              <given-names>PH</given-names>
            </name>
          </person-group>
          <article-title>Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration</article-title>
          <source>Anticancer Drugs.</source>
          <year>1996</year>
          <volume>7</volume>
          <issue>5</issue>
          <fpage>596</fpage>
          <lpage>603</lpage>
          <pub-id pub-id-type="doi">10.1097/00001813-199607000-00016</pub-id>
          <pub-id pub-id-type="pmid">8862729</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Esquis</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Consolo</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Magnin</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pointaire</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Moretto</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ynsa</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Beltramo</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Drogoul</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Simonet</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Benoit</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Rat</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Chauffert</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis</article-title>
          <source>Ann Surg.</source>
          <year>2006</year>
          <volume>244</volume>
          <issue>1</issue>
          <fpage>106</fpage>
          <lpage>112</lpage>
          <pub-id pub-id-type="doi">10.1097/01.sla.0000218089.61635.5f</pub-id>
          <pub-id pub-id-type="pmid">16794395</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ozols</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Speyer</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Sugarbaker</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Greene</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jenkins</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>CE</given-names>
            </name>
          </person-group>
          <article-title>Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer</article-title>
          <source>Cancer Res.</source>
          <year>1982</year>
          <volume>42</volume>
          <issue>10</issue>
          <fpage>4265</fpage>
          <lpage>4269</lpage>
          <pub-id pub-id-type="pmid">7105021</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Markman</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Intraperitoneal antineoplastic drug delivery: rationale and results</article-title>
          <source>Lancet Oncol.</source>
          <year>2003</year>
          <volume>4</volume>
          <fpage>277</fpage>
          <lpage>283</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(03)01074-X</pub-id>
          <pub-id pub-id-type="pmid">12732164</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blanco</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Giger</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Solass</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Cruciger</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Zieren</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Reymond</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC)</article-title>
          <source>Ann Surg Oncol.</source>
          <year>2013</year>
          <volume>20</volume>
          <issue>7</issue>
          <fpage>2311</fpage>
          <lpage>2316</lpage>
          <pub-id pub-id-type="doi">10.1245/s10434-012-2840-2</pub-id>
          <pub-id pub-id-type="pmid">23377563</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
